Want to see DCOY full AI Analyst Report?
DCOY Stock Chart & Stats
$5.81
-$0.06(-3.48%)
At close: 4:00 PM EST
$5.81
-$0.06(-3.48%)
Day’s Range― - ―
52-Week Range$4.32 - $416.05
Previous CloseN/A
VolumeN/A
Average Volume (3M)356.88K
Market Cap
$3.33M
Enterprise Value-$4.66M
Total Cash (Recent Filing)$7.82M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.94
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding531,968
10 Day Avg. Volume434,140
30 Day Avg. Volume356,875
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.64
Price to Sales (P/S)0.00
P/FCF Ratio-0.78
Enterprise Value/Market Cap-1.40
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.55
Enterprise Value/Ebitda0.36
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageZero reported debt gives the company durable financial flexibility typical of early-stage biotech. Without interest obligations, management can prioritize R&D spending and milestone-driven development, reducing insolvency risk and preserving optionality while pursuing clinical milestones.
Committed PIPE FinancingAn institutional PIPE that provides upfront capital and milestone-linked proceeds materially extends runway if milestones are met. The staged structure aligns investor incentives with clinical progress, enabling continued trial advancement without immediate full dilution and supporting longer-term program development.
Progress Vs. 2022 LossesSignificantly smaller losses versus 2022 indicate improved cost control or program prioritization. This durable trend suggests management has begun narrowing burn, increasing the likelihood that future capital will fund clearer, milestone-driven development rather than covering uncontrolled operating expansion.
Bears Say
Pre-revenue BurnThe absence of revenue combined with sustained negative operating and free cash flow means the business cannot self-fund development. Over months this structural cash burn necessitates external financing to continue trials, creating continual dilution or funding risk until commercial revenues or sustained profitability emerge.
Milestone-Linked Dilution RiskRelying on milestone-exercise warrants concentrates funding on binary clinical and regulatory outcomes. While it conserves upfront capital, it structurally ties capital availability to success, increasing shareholder dilution risk and making long-term financing contingent on meeting specific program milestones rather than predictable cash generation.
Shrinking Equity BaseA materially declining equity base reduces the company's capital cushion to absorb ongoing losses or unforeseen setbacks. This long-term erosion heightens vulnerability to adverse trial or regulatory outcomes and may increase the cost or difficulty of future financing, constraining strategic flexibility.
Decoy Therapeutics News
DCOY FAQ
What was Decoy Therapeutics’s price range in the past 12 months?
Decoy Therapeutics lowest stock price was $4.32 and its highest was $416.05 in the past 12 months.
What is Decoy Therapeutics’s market cap?
Decoy Therapeutics’s market cap is $3.33M.
When is Decoy Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Decoy Therapeutics’s earnings last quarter?
Currently, no data Available
Is Decoy Therapeutics overvalued?
According to Wall Street analysts Decoy Therapeutics’s price is currently Overvalued.
Does Decoy Therapeutics pay dividends?
Decoy Therapeutics does not currently pay dividends.
What is Decoy Therapeutics’s EPS estimate?
Decoy Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Decoy Therapeutics have?
Decoy Therapeutics has 531,968 shares outstanding.
What happened to Decoy Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Decoy Therapeutics?
Currently, no hedge funds are holding shares in DCOY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Decoy Therapeutics
Based in Cambridge, Massachusetts, Decoy Therapeutics Inc. is an early-stage biotechnology firm dedicated to tackling critical unmet medical needs. The company employs cutting-edge machine learning and AI technologies, alongside accelerated synthesis methods, to swiftly design, engineer, and manufacture innovative peptide conjugate drug candidates.
Technical Analysis
Biodexa Pharmaceuticals
―
Q/C Technologies
―
Scinai Immunotherapeutics
―
Oragenics
―
Onconetix
―
Ownership Overview
Options Prices
Currently, No data available
---